All In Biotech

Drug Trial Radar · NCT01004224

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

208

Actual

Start

Dec 11, 2009

Primary completion

Oct 8, 2018

Study completion Oct 8, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

Conditions

  • Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
  • Squamous Lung Cancer With FGFR1 Amplification
  • Bladder Cancer With FGFR3 Mutation or Fusion
  • Advanced Solid Tumors With FGFR1 Amplication
  • Advanced Solid Tumors With FGFR2 Amplication
  • Advanced Solid Tumors With FGFR3 Mutation

Interventions

  • BGJ398Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD)Time frame: 23 months

Locations

50 sites in 14 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Duarte, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • University of Colorado Dept. of Anschutz Cancer (3)

    Aurora, Colorado

  • Novartis Investigative Site

    New Haven, Connecticut

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center Onc. Dept..

    New York, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital Onc Dept

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Memphis, Tennessee

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Salt Lake City, Utah

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Saint-Herblain Cédex, France

  • Novartis Investigative Site

    Suresnes, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Marburg, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Meldola, FC, Italy

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.